检索结果 - Keyvan Shabafrouz

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study

    Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study 由 P Petit, Douglas Daoudlarian, S. Latifyan, H. Bouchaab, Nuria Mederos, J. Doms, Karim Abdelhamid, Nabila Ferahta, Lucrezia Mencarelli, Victor Joo, R Bartolini, A. Stravodimou, Keyvan Shabafrouz, G Pantaleo, Sarah Peters, Mariam Obeid

    出版 2024
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

    Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance 由 Filipe Martins, Sofiya Latifyan, Gerasimos P. Sykiotis, Faïza Lamine, Michel H. Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex‐Crosier, Thierry Küntzer, Olivier Michielin, Solange Peters, George Coukos, François Spertini, John A. Thompson, Michel Obéid

    出版 2019
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:

检索工具: